World Market (store)

Mark Cuban Cost Plus Drug Company and Vivid Clear Rx Team Up to Increase Access to Low-Priced Prescriptions

Retrieved on: 
Monday, April 22, 2024
Professional Services, Health, Insurance, Human Resources, General Health, Pharmaceutical, Public, Pharmacy, Cost Plus Drugs, World Market (store), Prescription, Patient, Multimedia, PBC

The Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs) and Vivid Clear Rx, a pass-through pharmacy benefit manager, have teamed up to make it easy for patients to access low-cost prescriptions.

Key Points: 
  • The Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs) and Vivid Clear Rx, a pass-through pharmacy benefit manager, have teamed up to make it easy for patients to access low-cost prescriptions.
  • View the full release here: https://www.businesswire.com/news/home/20240422460983/en/
    Now, eligible Vivid Clear Rx members have direct access to purchase affordable prescriptions and have them shipped through Cost Plus Drugs using their pharmacy benefit plan.
  • By collaborating together, Cost Plus Drugs and Vivid Clear Rx aim to control drug costs for health plans and patients nationwide.
  • The Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs) aims to fundamentally change the way the pharmaceutical industry operates.

Primestor Development Expands Retail Portfolio With The Acquisition of Esplanade Shopping Center in Oxnard, CA

Retrieved on: 
Monday, April 8, 2024
Commercial Building & Real Estate, Construction & Property, Restaurant, Bar, Other Retail, REIT, Other Construction & Property, Retail, Department Stores, Walmart, Esplanade, The Home Depot, NAP, Acquisition, BJ's, Investment, Multimedia, TJ Maxx, World Market (store), Nordstrom Rack, Commercial property

Primestor Development (Primestor), a leading minority-owned and led real estate development and investment firm based in Los Angeles, has announced the $90 million acquisition of the Esplanade Shopping Center, a 357,000-square-foot grocery-anchored retail community center in the coastal city of Oxnard, CA.

Key Points: 
  • Primestor Development (Primestor), a leading minority-owned and led real estate development and investment firm based in Los Angeles, has announced the $90 million acquisition of the Esplanade Shopping Center, a 357,000-square-foot grocery-anchored retail community center in the coastal city of Oxnard, CA.
  • View the full release here: https://www.businesswire.com/news/home/20240408316258/en/
    “The Esplanade Shopping Center provides the opportunity to acquire a 94% leased, institutional-quality, necessity retail asset located in a high-traffic area with a favorable mix of cash flow stability and embedded value-add potential,” noted Lonnie Vidaurri, Chief Investment Officer of Primestor.
  • Other tenants include Cost Plus World Market, Tillys, Boot Barn, In-N-Out Burger, BJ's Brewery and Restaurant, and more.
  • The company’s long-standing community engagement process is further underscored by its partnerships with local governments, community organizations, national credit tenants, and local stakeholders.

Provell Pharmaceuticals and Mark Cuban Cost Plus Drug Company Bring Leading Hypothyroid Drug, Euthyrox®, to U.S. Patients at Low-Cost Prices through Direct-to-Consumer Model

Retrieved on: 
Tuesday, March 12, 2024
Health, Hypothyroidism, Entrepreneurship, Disease, Partnership, Patient, Pharmacy, Merck, HONEY, Doctor of Philosophy, MD, Insurance, Merck Group, PBC, Plasma protein binding, Cost Plus Drugs, Blister, Marketing, FDA, NTI, Physician, World Market (store), Medicine, Pharmaceutical industry

HONEY BROOK, Pa., March 12, 2024 /PRNewswire/ -- Provell Pharmaceuticals, a healthcare company that distributes world-class, branded drugs at generic prices by eliminating middlemen markups, today announced a partnership with Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs) to offer patients direct access to a leading hypothyroid drug, Euthyrox®, at low-cost prices on the Cost Plus Drugs online platform.

Key Points: 
  • HONEY BROOK, Pa., March 12, 2024 /PRNewswire/ -- Provell Pharmaceuticals, a healthcare company that distributes world-class, branded drugs at generic prices by eliminating middlemen markups, today announced a partnership with Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs) to offer patients direct access to a leading hypothyroid drug, Euthyrox®, at low-cost prices on the Cost Plus Drugs online platform.
  • It is now offered in the U.S. through Cost Plus Drugs and in retail pharmacies.
  • "By working directly with online platforms such as Cost Plus Drugs, which shares our vision to make drugs affordable and accessible to all, we are disrupting the traditional model and conferring significant savings to patients."
  • Currently, the U.S. healthcare system consists of complex pricing mechanisms, for both brand and generic medications, that artificially inflate prices.

Community Health Systems Partners With Mark Cuban Cost Plus Drug Company to Address the Rising Cost of Drugs and Potential Drug Shortages

Retrieved on: 
Thursday, March 7, 2024
Managed Care, Hospitals, Pharmaceutical, Health, CYH, Hospital, Cost Plus Drugs, Doctor of Philosophy, MD, Partnership, Food, CHS, Norepinephrine, World Market (store), Community Health Systems, Intensive care medicine, ERS, Patient, Adrenaline, Patient safety, Community, Pharmaceutical industry

Community Health Systems, Inc. (NYSE: CYH) (CHS) will become the first national healthcare system to purchase select pharmaceutical supplies from Mark Cuban Cost Plus Drug Company (Cost Plus Drugs) as part of a new, collaborative relationship that promises to bring high-quality, lower cost drugs into the hospital setting.

Key Points: 
  • Community Health Systems, Inc. (NYSE: CYH) (CHS) will become the first national healthcare system to purchase select pharmaceutical supplies from Mark Cuban Cost Plus Drug Company (Cost Plus Drugs) as part of a new, collaborative relationship that promises to bring high-quality, lower cost drugs into the hospital setting.
  • Drug shortages – Cost Plus Drugs is focused on manufacturing drugs that are often in limited supply, threatening patient treatment and outcomes when shortages occur.
  • CHS and Cost Plus Drugs are working together to identify, prepare for, and mitigate potential future drug shortages in the hospital setting.
  • “Community Health Systems has stepped forward to consider important issues related to drug supply, drug costs, patient care and outcomes,” said Alex Oshmyansky, MD, PhD, Chief Executive Officer of Mark Cuban Cost Plus Drug Company.

SmithRx and Mark Cuban Cost Plus Drug Company Announce $9.5 Million in Client Savings Through Innovative Autoimmune Drug Sourcing

Retrieved on: 
Monday, March 4, 2024
Supply Chain Management, Online Retail, Professional Services, Health, General Health, Pharmaceutical, Health Insurance, Infectious Diseases, Retail, Insurance, Human Resources, Pharmacy, Cost Plus Drugs, Silicon, Venrock, PBC, World Market (store), Public, Patient, PBM, Prescription, Pharmaceutical industry

SmithRx, a transparent and 100% pass-through PBM, and Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs), announced today that in 6 months, they have saved SmithRx clients more than $9.5 million in the autoimmune category alone.

Key Points: 
  • SmithRx, a transparent and 100% pass-through PBM, and Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs), announced today that in 6 months, they have saved SmithRx clients more than $9.5 million in the autoimmune category alone.
  • This milestone has been achieved by strategically sourcing the lowest net cost autoimmune medications, including impactful transitions to cost-effective alternatives through Cost Plus Drugs.
  • This successful alliance combines SmithRx's patient-first approach with Cost Plus Drugs’ revolutionary drug pricing strategy to tackle the highest cost drug category for many employers.
  • The Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs) aims to fundamentally change the way the pharmaceutical industry operates.

Mark Cuban Cost Plus Drug Company and Sidecar Health team up to tackle rising healthcare costs

Retrieved on: 
Tuesday, January 9, 2024
Insurance, Specialty, Professional Services, Health Insurance, Health, Pharmaceutical, General Health, Retail, Online Retail, Sidecar Health, Leukemia, PBC, Cost Plus Drugs, Prescription, Pharmacy, Imatinib, Tablet, World Market (store), Gallup, Pharmaceutical industry

Sidecar Health, a transformative health insurance company giving its members control over costs and choice, announced today that it is teaming up with Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs) to help bring high-quality, lower-cost prescription drugs to Sidecar Health members.

Key Points: 
  • Sidecar Health, a transformative health insurance company giving its members control over costs and choice, announced today that it is teaming up with Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs) to help bring high-quality, lower-cost prescription drugs to Sidecar Health members.
  • Both Sidecar Health and Cost Plus Drugs were founded to address the issue of rising healthcare costs, which are often driven by lack of transparency and inefficient middlemen that inflate the overall cost of healthcare services.
  • Together, Sidecar Health and Cost Plus Drugs are fostering a healthcare landscape that is transparent, consumer-friendly, and genuinely cost-effective.
  • “Cost Plus Drugs and Sidecar Health are working together to change that.” By eliminating administrative complexities and offering transparency, Sidecar Health and Cost Plus Drugs are making prescription drugs more affordable and taking a significant step toward accessible healthcare for all.

Celiac Disease Foundation Teams Up with Mark Cuban Cost Plus Drug Company

Retrieved on: 
Wednesday, December 6, 2023
Retail, Health, Other Retail, Fitness & Nutrition, General Health, Pharmaceutical, Policy, Cost Plus Drugs, Food, Pharmacist, Risk, Mortality, Cardiovascular disease, Patient, Multimedia, Respiratory disease, Private sector, World Market (store), Social media, Cancer, Diagnosis, Coeliac disease, Lymphoma, Dentistry

The Celiac Disease Foundation , a global leader in celiac disease patient advocacy, today announces its new relationship with Mark Cuban Cost Plus Drug Company ( Cost Plus Drugs ) to provide resources for celiac disease patients and all consumers concerned about potential gluten in the company’s medications.

Key Points: 
  • The Celiac Disease Foundation , a global leader in celiac disease patient advocacy, today announces its new relationship with Mark Cuban Cost Plus Drug Company ( Cost Plus Drugs ) to provide resources for celiac disease patients and all consumers concerned about potential gluten in the company’s medications.
  • We are pleased and proud to join forces with Mark Cuban Cost Plus Drug Company to provide peace of mind to our celiac disease community.”
    Cost Plus Drugs’ pharmacy fulfillment partners can address inquiries regarding gluten content in medications, ensuring that those with celiac disease can confidently navigate their needs with the guidance of knowledgeable pharmacists.
  • “We are thrilled to be working with the Celiac Disease Foundation,” said Dr. Alex Oshmyansky, CEO of Mark Cuban Cost Plus Drug Company.
  • Living with celiac disease is a daily struggle, and it also increases the mortality risks for cancer, cardiovascular disease, and respiratory disease.

Mark Cuban Cost Plus Drug Company Teams Up With PBM PCA Rx

Retrieved on: 
Monday, December 18, 2023
PBC, Workforce, Doctor of Pharmacy, World Market (store), Rx, Cost Plus Drugs, PCA, Health, SAN, PBM, Pharmaceutical industry

SAN ANTONIO, Dec. 18, 2023 /PRNewswire-PRWeb/ -- [PCA Rx], a leading provider of pharmacy benefit management (PBM) services, is proud to announce a relationship with Mark Cuban Cost Plus Drug Company, PBC [Cost Plus Drugs], a trailblazer in drug pricing disruption. This collaboration aims to bring transparency, accessibility, and affordability to drug pricing for employers and individuals nationwide in an industry long plagued by hidden costs and lack of transparency.

Key Points: 
  • PCA Rx, a leading provider of pharmacy benefit management (PBM) services, is proud to announce a relationship with Mark Cuban Cost Plus Drug Company, a trailblazer in drug pricing disruption.
  • SAN ANTONIO, Dec. 18, 2023 /PRNewswire-PRWeb/ -- [ PCA Rx ], a leading provider of pharmacy benefit management (PBM) services, is proud to announce a relationship with Mark Cuban Cost Plus Drug Company, PBC [ Cost Plus Drugs ], a trailblazer in drug pricing disruption.
  • "We are excited to join forces with a like-minded company such as PCA Rx", said Alex Oshmyansky, CEO of Mark Cuban Cost Plus Drug Company.
  • "We are excited to join forces with a like-minded company such as PCA Rx", said Alex Oshmyansky, CEO of Mark Cuban Cost Plus Drug Company.

MARK CUBAN COST PLUS DRUG COMPANY AND DREXI TEAM UP TO DELIVER BETTER ACCESS TO MEDICATIONS AT AFFORDABLE AND SUSTAINABLE PRICES

Retrieved on: 
Tuesday, August 22, 2023
World Market (store), Cost Plus Drugs, Elijah Cummings Lower Drug Costs Now Act, Pharmacy, PBC, COST, GM, Patient, PBM, Health, Pharmaceutical industry, DALLAS, PHOENIX

PHOENIX and DALLAS, Aug. 22, 2023 /PRNewswire/ -- Drexi, a cutting-edge pharmacy benefit manager (PBM), and Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs), have teamed up to address one of the most pressing challenges in healthcare today: providing better access to the right drugs at affordable prices.

Key Points: 
  • PHOENIX and DALLAS, Aug. 22, 2023 /PRNewswire/ -- Drexi, a cutting-edge pharmacy benefit manager (PBM), and Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs), have teamed up to address one of the most pressing challenges in healthcare today: providing better access to the right drugs at affordable prices.
  • COST PLUS DRUG COMPANY AND DREXI TEAM UP TO DELIVER BETTER ACCESS TO MEDICATIONS AT AFFORDABLE AND SUSTAINABLE PRICES.
  • "As a practicing physician I saw first-hand the danger of patients not taking their medications because they couldn't afford them," said Alex Oshmyansky, CEO of Mark Cuban Cost Plus Drug Company.
  • "I founded the Mark Cuban Cost Plus Drug Company to help solve this problem and provide a way for patients to receive their medication at an affordable price.

TheracosBio and SmithRx Collaborate to Offer Newly Approved Diabetes Drug Brenzavvy™ (bexagliflozin) to Members with Type 2 Diabetes

Retrieved on: 
Thursday, August 17, 2023
Software, Biotechnology, Pharmaceutical, Health, Diabetes, Data Management, Health Technology, Technology, Diabetic neuropathy, Type 2 diabetes, Tenderness, Glycosuria, Dialysis, Gangrene, Pain, Urinary tract infection, 1946 Antarctica PBM Mariner crash, Incidence, Patient, Risk, PBM, Insulin, Ulcer, Pancreatitis, Diet, Cardiovascular disease, Urination, Vomiting, Cost Plus Drugs, Hypoglycemia, FDA, Death, Exercise, World Market (store), Chronic kidney disease, Amputation, Creatinine, Hypotension, Dehydration, Metabolic acidosis, Fever, CVD, Osteomyelitis, History, Abdominal pain, Ischemia, Erythema, Swelling, Type, Moyamoya disease, Knee, Infection, Pyelonephritis, Elijah Cummings Lower Drug Costs Now Act, Partnership, Hospital, Necrotizing fasciitis, Diabetic ketoacidosis, Pharmacy, Perineum, SGLT2, Ketoacidosis, Acute kidney injury, Frenz, Nausea, Female, Pharmaceutical industry, Dietary supplement, Medical imaging, Meat

Working with TheracosBio and Cost Plus Drugs, SmithRx now provides BRENZAVVY as an option following its launch in July 2023.

Key Points: 
  • Working with TheracosBio and Cost Plus Drugs, SmithRx now provides BRENZAVVY as an option following its launch in July 2023.
  • BRENZAVVY is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus.
  • Diabetes is the most expensive chronic condition in the U.S. and accounts for 1 of every 4 dollars spent on healthcare.
  • In patients with type 1 diabetes mellitus, BRENZAVVY significantly increases the risk of diabetic ketoacidosis, a life-threatening event, beyond background rate.